Waystar Holding Corp. (NASDAQ:WAY) is one of the The best digital health stocks to buy now.
On October 30, 2025, following the company’s third-quarter earnings, Mizuho Securities raised its target from $48 to $50 and reiterated an Outperform rating, citing strong demand for Waystar’s revenue cycle management solutions. The firm highlighted that the adoption of AI-powered claim denial tools was a key factor in the company’s above-consensus performance.
Waystar Holding Corp. (NASDAQ:WAY) released its third quarter report on October 29, 2025. The double-digit growth came from steady transaction volume, expanding customer adoption, and early cross-selling of Iodine Software, which lifted revenue 12% to $268.7 million and kept adjusted EBITDA strong at $112.7 million with a 42% margin. Cost discipline and scale did the rest, turning more of every dollar into profit and lifting net income to $30.6 million. Management raised full-year targets, indicating confidence that Iodine’s integration and portfolio can build momentum through 2026: revenue to $1.085-$1.093 billion and adjusted EBITDA to $451-$455 million.
Waystar Holding Corp. (NASDAQ:WAY) is a healthcare payment and revenue cycle technology provider. Its cloud-based software is used by hospitals, physician groups and other care organizations to manage claims processing, billing, prior authorizations and patient financial interactions.
While we recognize WAY’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.
READ NEXT: 30 stocks that should double in 3 years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None.